EXAS Stock Price Exact Sciences Corp Stock Quote U.S.: Nasdaq

The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. You can find your newly purchased EXAS stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. The scores are based on the trading styles of Value, Growth, and Momentum.

Exact Sciences MarketRank™ Forecast

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Exact Sciences updated its FY 2023 earnings guidance on Wednesday, June, 28th.

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).

Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

Reports record results, raises full-year guidance, accelerates path to positive free cash flow First  quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 milli… Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million … BOULDER, Colo.–(BUSINESS WIRE)– #NGS–Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporat… One share of EXAS stock can currently be purchased for approximately $78.40. Exact Sciences’ stock is owned by many different retail and institutional investors.

These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets.

How we use your personal data

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program anal… Kevin Conroy, Exact Sciences CEO, joins ‘Fast Money’ to discuss Exact Sciences latest trial results for its colo-rectal cancer tests, Cologuard.

Exact Sciences’s Q3 earnings are confirmed for Thursday, November 2, 2023. Get stock recommendations, portfolio guidance, https://1investing.in/ and more from The Motley Fool’s premium services. EXAS earnings call for the period ending September 30, 2022.

Sign up for a brokerage account on Public

Please see Open to the Public Investing’s Fee Schedule to learn more. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

• Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
• Larry Ramer has conducted research and written articles on U.S. stocks for 15 years.
• A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
• It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
• The monthly returns are then compounded to arrive at the annual return.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company’s employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. In its Q2 Shareholder Letter, Roku noted that “While Q2 Platform revenue exceeded our expectations, the macro environment continued to create uncertainty with the total U.S. advertising market flat (year-over-year) in Q2.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. EXAS’s beta can be found in Trading Information at the top of this page.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.

You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, nostro vostro loro open a brokerage account, or engage in any investment strategy. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Indeed, one of my family members recently had to wait three months before receiving a colonoscopy that she requested. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard® is more effective when compared to hypothetical blood-based screening1-3 MADISON, Wis. , Ma… According to 17 analysts, the average rating for EXAS stock is “Buy.” The 12-month stock price forecast is $94.86, which is an increase of 21.00% from the latest price.

Meanwhile, the company is intensively working to expand its business in Asia, and that initiative could bear fruit by next year. Product offerings and availability vary based on jurisdiction. When you see EXAS stock appear in the results, tap it to open up the purchase screen. There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.